Citius Pharmaceuticals, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Citius Pharmaceuticals, Inc. (CTXR) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$3.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$3.06M.
- Citius Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$6.88M.
- Citius Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$1.17M.
- Citius Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$784.36K.
- Citius Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$2.31M.
- Citius Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$287.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.06M 10-Q · filed 2026-08-14 | -$9.94M derived: sum of 2 quarters · filed 2026-08-14 | -$11.11M 10-Q · filed 2026-08-14 | -$11.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$6.88M 10-Q · filed 2026-05-15 | -$8.05M 10-Q · filed 2026-05-15 | -$8.84M derived: sum of 3 quarters · filed 2026-05-15 | -$9.25M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$1.17M 10-Q · filed 2026-02-13 | -$1.96M derived: sum of 2 quarters · filed 2026-02-13 | -$2.37M derived: sum of 3 quarters · filed 2026-08-14 | -$2.97M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | -$784.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$1.20M derived: sum of 2 quarters · filed 2026-08-14 | -$1.79M derived: sum of 3 quarters · filed 2026-08-14 | -$2.31M 10-K · filed 2025-12-23 |
| 2025-06-30 | -$414.00K 10-Q · filed 2026-08-14 | -$1.01M derived: sum of 2 quarters · filed 2026-08-14 | -$1.52M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$595.00K 10-Q · filed 2026-05-15 | -$1.11M 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | -$513.00K 10-Q · filed 2026-02-13 | |||
| 2024-09-30 | -$287.00K 10-K · filed 2025-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |